After images of an the new mid-sized electric crossover were leaked by the Chinese MIIT, Nissan pulled the wraps off its all-new NX8 – and it looks so good, I’m wondering if it couldn’t spearhead the brand’s American turnaround. Nissan has had a rough go of it in the US, if not, well – everywhere of late.… Continue reading The electric crossover that could help save Nissan: meet the all-new NX8
Tag: Manufacturing
XCMG Flagship Mining Trucks Depart for World-Class Simandou Project, Delivering Key Chinese Technology to Global Mining Development
XUZHOU, China, Dec. 8, 2025 /PRNewswire/ — XCMG Machinery (SHE:000425) has commenced the shipment of its flagship mining trucks from its intelligent manufacturing base in China. The equipment is destined for the SimFer mine, part of the Simandou iron ore project in Guinea, West Africa, marking a significant milestone and showcasing Chinese manufacturing excellence at the… Continue reading XCMG Flagship Mining Trucks Depart for World-Class Simandou Project, Delivering Key Chinese Technology to Global Mining Development
CIMC Unveils New Global Brand Logo and Visual Identity System
SHENZHEN, China, Dec. 7, 2025 /PRNewswire/ — On December 5, 2025, China International Marine Containers (Group) Co., Ltd. (CIMC) unveiled its new brand logo and visual identity system to a global audience. Marking the company’s most significant brand upgrade in nearly fifteen years, the launch signals the beginning of a new chapter as CIMC accelerates… Continue reading CIMC Unveils New Global Brand Logo and Visual Identity System
Can E-rallying in an Alpine live up to the Monte Carlo dream?
A British Isles crew kept up the best traditions of entente cordiale on the recent FIA e-Rallye Monte-Carlo as they twirled a pretty, French blue Alpine A290 GTS around some of the world’s most famous rally stages. Richard Crozier and co-driver Craig Parry joined forces for the first time to dive into the oldest, most… Continue reading Can E-rallying in an Alpine live up to the Monte Carlo dream?
CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
SHANGHAI, Dec. 7, 2025 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product candidate, CT0596, for the treatment of relapsed/refractory multiple myeloma (R/R MM) was presented in a poster at the 67th American Society of… Continue reading CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
IASO Bio Presents Updated Results for Equecabtagene Autoleucel in High-Risk Newly Diagnosed Multiple Myeloma Patients at 2025 ASH
SHANGHAI and NANJING, China and PLEASANTON, Calif., Dec. 7, 2025 /PRNewswire/ — IASO Biotechnology (“IASO Bio”), a commercial-stage biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of novel cell therapies and biologics for hematologic malignancies and autoimmune diseases, announced the oral presentation of updated clinical data for its independently developed, fully human BCMA-targeted… Continue reading IASO Bio Presents Updated Results for Equecabtagene Autoleucel in High-Risk Newly Diagnosed Multiple Myeloma Patients at 2025 ASH
Hydron Energy Demonstrates Low-Cost Production of Xenon with Negative Carbon Footprint for Satellite Propulsion
NORTH VANCOUVER, BC, Dec. 7, 2025 /PRNewswire/ – Hydron Energy, a leading innovator in clean fuel and gas separation technologies, today announced the successful demonstration of carbon-negative Xenon and Krypton production from air. The initiative focused on application of Hydron’s next generation metal-organic framework (MOF) in the company’s INTRUPTor™ gas separation platform for direct air… Continue reading Hydron Energy Demonstrates Low-Cost Production of Xenon with Negative Carbon Footprint for Satellite Propulsion
ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
SAN FRANCISCO and SUZHOU, China, Dec. 7, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, announced the initial data of the first-in-human trial of IBI3003, a novel trispecific… Continue reading ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
The 4th China International Supply Chain Expo Set for Beijing in June 2026
Sustained Worldwide Outreach Drives Greater Collaboration Opportunities BEIJING, Dec. 7, 2025 /PRNewswire/ — The 4th China International Supply Chain Expo (“CISCE,” “the Expo”) will be held in Beijing from June 22 to 26, 2026. To date, more than 300 companies have signed up to exhibit, with preparations moving forward smoothly. Continue Reading Canada-China Forum on… Continue reading The 4th China International Supply Chain Expo Set for Beijing in June 2026
CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
SHANGHAI, Dec. 7, 2025 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product candidate, CT0596, for the treatment of relapsed/refractory multiple myeloma (R/R MM) was presented in a poster at the 67th American Society of… Continue reading CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting